{"disease":{"id":"chronic-plaque-type-psoriasis","name":"chronic plaque type psoriasis"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02074982","title":"Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":676,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT01640951","title":"4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":675,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT03504852","title":"Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":331,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT02471144","title":"Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":162,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT04207801","title":"A Phase II Study to Evaluate Efficacy & Safety of AUR101 in Patients of Moderate-to-Severe Psoriasis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":90,"lead_sponsor_name":"Aurigene Discovery Technologies Limited","has_results":true},{"nct_id":"NCT03668613","title":"Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":84,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT03553823","title":"Comparison of Secukinumab Versus Guselkumab in Clearing Psoriatic Plaques Refractory to Ustekinumab","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true}],"total":7},"guidelines":[],"source":"Drug Landscape verified database"}